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Abstract: BACKGROUND Positron emission tomography (PET) targeting the prostate-specific mem-
brane antigen (PSMA) has superior sensitivity over conventional imaging (CI) to stage prostate cancer
(PCa) and therefore is increasingly used in staging to stratify patients before radical therapy. Whether
this improved diagnostic accuracy translates into improved outcome after radical prostatectomy (RPE)
has not yet been shown. Therefore, the aim of this study was to compare the oncological outcome after
RPE between patients that underwent preoperative staging with CI or PSMA-PET for intermediate and
high-risk PCa. METHODS We retrospectively selected all patients that underwent RPE for intermediate-
or high-risk PCa at our institution before PSMA-PET introduction (between March 2014 and September
2016) and compared the oncologic outcome of patients staged with PSMA-PET (between October 2016
and October 2018). Oncological pre-surgical risk parameters (age, PSA, D’Amico score, biopsy-ISUP, and
cT stage) were compared between the groups. Oncological outcome was determined as PSA persistence,
nerve-sparing rate, and surgical margin status. Wilcoxon rank-sum, Fisher’s, and chi-square tests where
used for statistical testing. RESULTS One hundred five patients were included, 53 in the CI group and
52 in the PSMA-group. Patients in the PSMA group had higher ISUP grade (p < 0.001) and D’Amico
score (p < 0.05). The rate of free surgical margins and PSA persistence after RPE was 64% and 17% for
the CI and 77% and 6% for the PSMA group (p = 0.15 and 0.13, respectively). Subgroup analysis with
high-risk patients revealed PSA persistence in 7% (3/44) in the PSMA group and 25% (7/28) in the CI
group (p = 0.04). Limitations include the retrospective design and choline-PET for some patients in the
CI group. CONCLUSION Immediate outcome after RPE was not worse in the PSMA group compared
with the CI group, despite a higher-risk cohort. In a comparison of only high-risk patients, PSMA-PET
staging was associated with a significantly lower rate of postsurgical PSA persistence.
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Abstract
Background Positron emission tomography (PET) targeting the prostate-specific membrane antigen (PSMA) has superior sen-
sitivity over conventional imaging (CI) to stage prostate cancer (PCa) and therefore is increasingly used in staging to stratify
patients before radical therapy. Whether this improved diagnostic accuracy translates into improved outcome after radical
prostatectomy (RPE) has not yet been shown. Therefore, the aim of this study was to compare the oncological outcome after
RPE between patients that underwent preoperative staging with CI or PSMA-PET for intermediate and high-risk PCa.
Methods We retrospectively selected all patients that underwent RPE for intermediate- or high-risk PCa at our institution before
PSMA-PET introduction (between March 2014 and September 2016) and compared the oncologic outcome of patients staged with
PSMA-PET (between October 2016 and October 2018). Oncological pre-surgical risk parameters (age, PSA, D’Amico score,
biopsy-ISUP, and cT stage) were compared between the groups. Oncological outcome was determined as PSA persistence,
nerve-sparing rate, and surgical margin status. Wilcoxon rank-sum, Fisher’s, and chi-square tests where used for statistical testing.
Results One hundred five patients were included, 53 in the CI group and 52 in the PSMA-group. Patients in the PSMA group had
higher ISUP grade (p < 0.001) and D’Amico score (p < 0.05). The rate of free surgical margins and PSA persistence after RPE
was 64% and 17% for the CI and 77% and 6% for the PSMA group (p = 0.15 and 0.13, respectively). Subgroup analysis with
high-risk patients revealed PSA persistence in 7% (3/44) in the PSMA group and 25% (7/28) in the CI group (p = 0.04).
Limitations include the retrospective design and choline-PET for some patients in the CI group.
Conclusion Immediate outcome after RPE was not worse in the PSMA group compared with the CI group, despite a higher-risk
cohort. In a comparison of only high-risk patients, PSMA-PET staging was associated with a significantly lower rate of postsurgical
PSA persistence.
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Introduction
Several single-center studies suggested an improved sensitiv-
ity of positron emission tomography (PET) targeting the
prostate-specific membran antigen (PSMA) for staging
intermediate- to high-risk prostate cancer (PCa) [1–4].
Recently this benefit of PSMA staging has been confirmed
in a randomized prospective multicenter trial (proPSMA),
which revealed an improved sensitivity for nodal and distant
metastasis for PSMA-PET compared with conventional imag-
ing (CI) [5]. Furthermore, in a direct comparison with mag-
netic ressonance imaging (MRI), PSMA-PET/MRI has a
higher reported sensitivitiy for extracapsular extension and
seminal vesicle invasion, of up to 94% and 95% [6–8].
Six publications investigating the impact of PSMA-PET on
management were published between 2018 and 2019 includ-
ing a total of 396 patients, showing a range of management
change from 21 to 52% [3, 8–12]. PSMA-PETwas considered
useful for improved patient selection for focal therapies, or to
change therapy modalities based on the PET findings as
shown also in a study from our group that found a change in
management in 27% of patients based on the staging PSMA-
PET [10, 13]. Furthermore, some preliminary results suggest
that PSMA-PET could further improve the selection of pa-
tients for pelvic nodal dissection (pLND), considering that
up to 47% of the detected lymph nodemetastasis are not found
within the regular pLND areas [14]. The accuracy of PSMA-
PET to select patients for pLND is as high as the existing
nomograms currently used, and there are first results showing
that a combination of quantitative assessment of PSMA in the
primary tumor with visual analysis of the nodes on PET could
improve selection for pLND even further [7, 15].
In the light of these data, it could be expected that the
higher sensitivity of PSMA-PET for metastasis detection leads
to a better selection of patients for radical prostatectomy
(RPE). After surgery, immediate oncological success of the
treatment can be measured by the rate of negative surgical
margins and an undetectable PSA (< 0.1 ng/ml) after surgery.
PSA persistence 6 weeks after RPE is associated with worse
oncological outcome [16].
However, the surgical outcome after RPE for patients that
underwent PSMA-PET for staging PCa has not yet been in-
vestigated. Therefore, we aimed to compare the immediate
outcome after RPE between patients with intermediate and
high-risk PCa, who underwent the same pre-surgical and sur-
gical procedures in a single center, staged with either CI or
68Ga-PSMA-11 PET/CT or PET/MR.
Patients and methods
Study population
This retrospective study included patients with intermediate-
or high-risk PCa who underwent RPE between March 2014
and October 2018 and had a preoperative multiparametric
MRI (mpMRI) followed by a template saturation biopsy (20
or more cores). All consecutive patients surgically treated be-
tween March 2014 and September 2016 with conventional
staging, including choline PET/CT, contrast enhanced CT,
bone scan, or abdominal MRI, compose the CI group.
PSMA-PET was introduced in our institution in April 2016.
Therefore, patients surgically treated between October 2016
and October 2018 were staged with PSMA-PET and compose
the PSMA group (Fig. 1). Between March 2014 and October
2018, there was no change in the standard surgery procedures
for RPE and no change in the operating team. Relevant clin-
ical and pathological information was collected from the pa-
tients’medical charts. The two groups were compared regard-
ing initial risk according to both D’Amico risk classification
and the recently published criteria in the proPSMA trial, as
well as age, TNM stage, PSA level, and both biopsy and RPE
specimen–derived ISUP grade groups. Most of the PSMA
cohort (49/52) was analyzed in the recently published out-
come paper on change in management [13]. The local ethics
committee approved the study protocol, and all patients gave a
general written informed consent for retrospective use of their
data (BASEC Nr. 2018-01284).
Imaging techniques and analysis
Patients underwent a clinical routine 68Ga-PSMA-11 PET/
MRI (SIGNA PET/MR, GE Healthcare, Waukesha, WI,
USA) or 68Ga-PSMA-11 PET/CT (Discovery VCT 690 or
Discovery MI PET/CT, GE Healthcare, Waukesha, WI,
USA). Images were acquired 60 min after injection of 68Ga-
PSMA-11 (mean dose ± standard deviation (SD), 131 ±
19 MBq, range 81–160 MBq). To reduce activity in the uri-
nary system, furosemide was injected intravenously 30 min
prior to the tracer injection (0.13 mg/kg) and patients were
asked to void prior to the scan. The institutional protocol
was in agreement with the EANM and SNMMI procedure
guidelines [17]. Studies were reported in clinical routine by
experienced dual board-certified radiologists and nuclear
medicine physicians, avoiding known PSMA-positive pitfalls
[18, 19].More details regarding imaging protocol and analysis
are given in the supplements.
Radical prostatectomy and lymphadenectomy
All surgical procedures were performed in form of a robot-
assisted transperitoneal laparoscopic RPE with bilateral
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extended pLND using the four-arm Da Vinci S system
(Intuitive Surgical, Inc., USA) by experienced urologists at
our institution as described earlier [20]. Extended pLND is a
standard procedure for all intermediate- and high-risk PCa
patients that undergo RPE in our hospital irrespective of the
result of PSMA-PET imaging and included the external iliac,
obturator, and internal iliac (hypogastric) lymph nodes with an
upper resection boundary defined by the crossing of the ureter
over the common iliac artery. If PSMA-PET revealed nodal
metastases in the pelvis outside the template (e.g., common
iliac nodes), these nodes were also removed if technically
possible. Nerve-sparing was performed if imaging showed
no cancer close to the bundle region, capsular involvement,
or suspicion for extracapsular extension. In all cases with
nerve-sparing, frozen section was used during surgery and
the neurovascular bundle removed, if the prostate surface
showed cancer.
Outcome definitions
Surgical outcome was assessed by the rate of nerve-sparing in
each group (patient-wise and side-wise), surgical margins sta-
tus (R0 or R1), PSA persistence after surgery (defined as PSA
level ≥ 0.1 ng/ml measured 6 weeks after surgery) [16].
Information was collected from patients’ charts.
Statistical analysis
Statistical analysis was performed with R version 3.6.3.
Descriptive statistics were expressed as median and interquar-
tile range (IQR) (25th and 75th percentiles (Q1-Q3)), as well
as counts and percentages. To compare different groups, the
following statistical tests were performed: Wilcoxon rank-
sum test, Fisher’s exact test, and chi-square test of indepen-
dence, where appropriate. All tests were two-tailed. A p value
< 0.05 was considered indicative of significant differences. In
the subgroup analysis, we did not correct for multiple com-
parisons due to the exploratory nature of the analysis.
Results
One hundred five patients were included, 53 in the CI group
and 52 in the PSMA group (Table 1). Information about im-
aging staging for distant disease in the CI group is shown in
Table 2; of note, 24 (45%) patients underwent choline PET;
21 of them had high-risk disease representing 75% of the
high-risk patients (21 of 28). In the PSMA group, 42 patients
underwent 68Ga-PSMA-11 PET/MRI and ten patients had
PET/CT. No patient had findings of M1b or M1c disease on
CI or PSMA-PET. Two patients with PSMA-positive com-
mon iliac nodes were still considered as pelvic disease and
referred for RPE.
Comparison of patients and disease characteristics
between the groups
Characteristics of both groups are shown in Table 1 and
Fig. 2. There was no difference between PSMA and CI
groups regarding age, initial PSA level, and clinical T-
stage. However, in the PSMA group significantly more
patients had high-risk disease compared with the CI
group, mainly due to higher biopsy ISUP grade
(p < 0.001). In the CI group, the most frequent tumor bi-
opsy ISUP grade was 2 (32%, 17/53) and only 53% (28/
53) of the patients had high-risk disease according to
D’Amico score, while in the PSMA group, around half
of the patients (48%, 25/52) presented ISUP grade 4 tu-
mors and 84.5% (44/52) had high-risk disease. After RPE,
pathological tumor grade confirmed the difference be-
tween the cohorts, with 24.5% of patients presenting tu-
mors grade 4 or 5 in the CI group and 44% in the PSMA
group. The number of resected lymph nodes at extended
Fig. 1 Flow diagram of inclusion
of patients. ADT = androgen
deprivation therapy; CI =
conventional imaging; mpMRI =
multiparametric magnetic
resonance imaging; PSA =
prostate-specific antigen; PSMA-
PET = positron emission
tomography with prostate-
specific membrane antigen;
RPE = radical prostatectomy
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pLND was similar for both groups, with median of 21
nodes in both (mean 20.4 nodes, IQR 15–24 in the CI
group and mean 22.6 nodes, IQR 17–26 in the PSMA
group). pN1 disease was found in 7 patients (13.5%) in
the CI group and in nine (17%) in the PSMA group (p =
0.8), with a mean of metastatic nodes of 3 (mean 1.0,
range 1–11) and 2.5 (mean 2.0, range 1–7), respectively.
Thirty-three patients had pT2 and 20 pT3 disease in the
CI group, compared with 35 and 17 in the PSMA group,
respectively. Among the patients with pT2 disease, the
rate of R1 margins was 15% (5/33) in the CI group and
8.6% (3/35) in the PSMA group.
Comparison of outcome between the groups
Results of this section are presented in Table 3 and illustrated
in Fig. 3.
In a patient-based analysis, the rate of nerve-sparing
was similar between the groups, with 60% (32/53) in the
CI group versus 63% (33/52) in the PSMA group
(p > 0.9). However, in the CI group, bilateral nerve-
sparing was more often performed (56%, 18/32) than in
the PSMA group (30%, 10/33). Among patients with any
nerve-sparing, the rate of negative surgical margins was
69% (22/32) in the CI-group and 91% (30/33) for the
PSMA-group. Of note, no patient in the PSMA-group
who had nerve-sparing had PSA persistence (Fig. 4),
against 3 patients (9%) in the CI group (two with R1
and one with R0 resection). For high-risk patients






Age median (IQR) 65 (62–69) 65 (61–69) > 0.9
PSA median (IQR) 8 (6–13) 9 (5–14) 0.8
< 10 32 (60.5%) 28 (54%)
10–20 12 (22.5%) 19 (36.5%)
> 20 9 (17%) 5 (9.5%)
cT stadium n (%) 0.11
T1c 46 (87%) 37 (71%)
T2a 2 (3.5%) 7 (13.5%)
T2b 1 (2%) 0
T2c 3 (5.5%) 7 (13.5%)
T3 1 (2%) 1 (2%)
ISUP grade group on biopsy n (%) < 0.001
2 17 (32%) 4 (7.5%)
3 13 (24.5%) 8 (15.5%)
4 8 (15%) 25 (48%)
5 15 (28.5%) 15 (29%)
D’Amico risk group n (%) < 0.001
Intermediate 25 (47%) 8 (15.5%)
High 28 (53%) 44 (84.5%)
Risk according to proPSMA trial* n (%) 0.002
Low 12 (22.5%) 1 (2%)
Intermediate 3 (6%) 2 (4%)
High 38 (71.5%) 49 (94%)
ISUP grade group on prostatectomy specimen n (%) 0.008
1 0 1 (2%)
2 18 (34%) 5 (9.5%)
3 22 (42%) 23 (44%)
4 4 (7.5%) 12 (23%)
5 9 (17%) 11 (21%)
*According to criteria used in the proPSMA trial (high-risk: ISUP ≥ 3, PSA ≥ 20 ng/ml, or clinical T3 or more)
[5], low risk was considered as ISUP ≤ 2, PSA< 10, and cT1c
Table 2 Imaging modalities for staging of distant disease before radical
prostatectomy in the conventional imaging group (n = 53), according to
disease risk using D’Amico risk score
Intermediate risk High risk Total
Choline PET 3 21 24
Bone scan and/or CT 1 4 5
No imaging 20* 0 20
Data not available 1 3 4
Total 25 28 53
*13 patients had ISUP grade 2 on biopsy, and therefore, no imaging was
indicated to investigate distant metastasis according to the updated
European Association of Urology guideline. The remaining 7 patients
had ISUP grade 3 on biopsy, T1c disease and PSA < 10 ng/ml
CT computed tomography
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according to D’Amico risk score, the patient-based rate of
nerve-sparing in the PSMA group was 66% and 46% in
the CI group (p = 0.2).
Overall, the rate of negative surgical margins and undetect-
able PSA after RPE was slightly higher in the PSMA group
(p = 0.15 and p = 0.13, respectively). For high-risk patients,
the difference is accentuated: 57% of R0 and 75% of unde-
tectable PSA after RPE in the CI group and 77% and 93% in
the PSMA group (p = 0.12 and 0.04), respectively. Among
patients with R0, the rate of PSA persistence was 8.8%
(3/34) in the CI group and 2.4% (1/41) in the PSMA group
(Fig. 5).
Discussion
This is the first cohort comparison of oncological post-RPE
outcome in patients that underwent either PSMA-PET or CI
for staging. Our analysis revealed an improvement of surgical
planning with a higher rate of unilateral nerve-sparing and a
lower rate of positive surgical margins, most likely due to
better preoperative identification of the location of the tumor
using PSMA-PET imaging. Furthermore, the hypothesis that
patient selection with PSMA-PET for RPE was superior com-
pared with CI was confirmed with only one versus three pa-
tients that had PSA persistence despite R0 resection. Despite
higher biopsy ISUP grades and fewer D’Amico intermediate-
risk patients, the post RPE outcome regarding PSA persis-
tence was non-inferior between both groups. Subgroup anal-
ysis between high-risk patients showed that the PSMA group
had a significantly lower rate of PSA persistence 6 months
after RPE compared with the CI group.
Our findings are supported by the increasing number of
publications that show a higher accuracy for 68Ga-PSMA-
11 PET for pelvic lymph nodes and distant metastasis.
Recently, a randomized prospective trial showed that CI
underestimates the number of patients with distant disease
[5]. Looking in-depth into the data of this trial, 22 of 150
patients were suspected to have distant disease, with 11
false-negative cases by CI. Assuming that 128 patients
would have been undergoing RPE, in these 11 cases,
PSA persistence would be expected (8.6%); interestingly,
this number corresponds well with the 8.8% of cases with
PSA persistence despite R0 resection in our CI group. For
the PSMA group, this result is significantly better in the



































































Fig. 2 Comparison of oncological pre-surgical risk parameters between
the CI and PSMA groups. Data show a relatively similar distribution
between the two groups for clinical T stadium but a higher risk cohort
in the PSMA group when compared with the CI group according to ISUP
grade groups (on biopsy and on radical prostatectomy (RPE) specimen)
and both D’Amico risk classification and criteria used in the proPSMA
trial
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distant disease and only two false-negative cases and,
therefore, an expected PSA persistence rate after R0
RPE of 1.6% for 122 PSMA-PET negative cases. Again,
this number is corresponding well to the PSA persistence
despite R0 resection in our PSMA-group of 2.4%.
The superior rate of R0 margins in cases of unilateral
nerve-sparing resections further supports the so far retrospec-
tively collected data that shows PSMA-PET can improve local
staging and guide the surgeon in the selection of appropriate
safety margins (Fig. 4).
Subgroup analysis with inclusion of only high-risk patients
accentuated the difference of outcome between the CI and
PSMA groups, with the latter achieving a significantly lower
rate of PSA persistence after RPE (p = 0.04) despite the
relatively small cohort size. This is in accordance with our
recently published study that showed PSMA-PET has a higher
impact on management on high-risk patients [13].
Of course, also PSMA-PET can miss distant disease, as in
our cohort one patient with a strongly PSMA-positive primary
tumor and one PSMA-positive internal iliac node had PSA
persistence of 0.82 ng/ml despite RPE with R0 resection and
nodal dissection with only one positive internal iliac node
lymph node. He underwent salvage radiotherapy including
the lymphatic drainage that reduced the PSA to 0.3 ng/ml
(Fig. 5). On the other hand, there were three patients with
PSA persistence despite R0 resection in our CI group, with
PSA values of 0.33 ng/ml, 5.27 ng/ml, and 11.9 ng/ml. For the
first patient, salvage radiotherapy was performed 6 months
Fig. 3 Comparison of outcome between the CI and PSMA groups. Venn
diagrams showing the distribution of the 105 patients (represented as
dots) in three sets: those who had nerve-sparing, those who had free
surgical margins (R0), and those who had PSA persistence after radical
prostatectomy (RPE). In the CI group, the intersection between the sets of
patients who had nerve-sparing and R0 has fewer patients (21) than in the
PSMA group (30). In the CI group, three patients with nerve-sparing had
PSA persistence, against none in the PSMA group. Patients who are not
placed inside any of the three sets are those who did not have nerve-
sparing, had positive margins (R1), and had undetectable PSA after
RPE (five patients in the CI group and six in the PSMA group)
Table 3 Comparison of outcome between the PSMA and CI groups










Nerve-sparing n (%) 32 (60%) 33 (63%) > 0.9 13 (46%) 29 (66%) 0.2
Surgical margins n (%) 0.15 0.12
R0 34 (64%) 41 (79%) 16 (57%) 34 (77%)
R1 19 (36%) 11 (21%) 12 (43%) 10 (23%)
PSA status after RPE n (%) 0.13 0.04
< 0.1 ng/ml 44 (83%) 49 (94%) 21 (75%) 41 (93%)
≥ 0.1 ng/ml 9 (17%) 3 (6%) 7 (25%) 3 (7%)
*According to D’Amico score
PSA: prostate-specific antigen; RPE: radical prostatectomy
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after surgery. The second patient had subsequent PSMA-PET
imaging showing distant disease (Fig. 6), and for the third
patient, with a PSA of 11.9 ng/ml, nodal-positive disease,
and a negative choline PET, ADT was started.
The retrospective nature for outcome analysis is always a
limiting factor, especially when analyzing postsurgical out-
comes, given that there are many factors affecting RPE out-
come. Preoperative mpMRI affects the rate of positive
surgical margins in patients with clinical T1c disease. MRI-
targeted biopsy, together with the number of systematic
cores, influences histopathological classification of tumors
[21, 22]. We therefore selected patients from one center,
which underwent mpMRI, MRI-guided and saturation tem-
plate biopsy followed by robotic surgery with pelvic lymph
node dissection within 4.5 years. Even though most patients
staged with PSMA-PET were operated in more recent years
Fig. 5 68Ga-PSMA-11 positron emission tomography/magnetic reso-
nance imaging (PET/MRI) from the only patient who had postsurgical
prostate-specific antigen (PSA) persistence with free surgical margins in
the PSMA group. 68Ga-PSMA-11 PET/MRI studies in different moments
of a 73-year-old patient with a T1c tumor, Gleason score 4 + 5 = 9 on
biopsy, and initial PSA level of 25.6 ng/ml. (A) Staging PET showed the
primary tumor with a high PSMA uptake (SUVmax 25) and a single
PSMA-positive iliac internal lymph node (arrows). The patient
underwent radical prostatectomy with extended pelvic lymph node dis-
section (R0, pN1, 1/25) but had PSA persistence (0.82 ng/ml). (B)
Subsequent PET showed no suspicious lesion and the patient underwent
salvage radiotherapy with a PSA drop to 0.35 ng/ml
Fig. 4 Extracapsular extension shown on 68Ga-PSMA-11 positron
emission tomography/magnetic resonance imaging (68Ga-PSMA-11
PET/MRI). Staging prostate magnetic resonance imaging (bottom) and
68Ga-PSMA-11 PET/MRI (top) of a 75-year-old patient with a T1c tu-
mor, Gleason score 4 + 3 = 7 on biopsy, and initial PSA level of 16 ng/ml.
Imaging shows a lesion involving the transition zone of the prostatic base
(A) and the anterior apex (B). MRI (diffusion-weighted images and T2-
weighted fast recovery fast spin-echo sequence (FRFSE)) shows a bilat-
eral PIRADS 3 lesion in the peripheral zone without suspicion of
extracapsular extension. 68Ga-PSMA-11 PET/MRI (FRFSE and fused
PET/MRI) shows increased bilateral PSMA uptake, suggestive of signif-
icant cancer with suspicion of extracapsular extension on the left side
(arrow). Surgery was performed without nerve spearing and histopathol-
ogy confirmed pT3a disease
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comparedwith the CI group, the fact that we focused only on
the immediate post-surgical outcomeand that the therapeutic
approach did not change in our department within this time
frame should reduce a potential bias in favor to PSMA-PET.
Another limitation of our non-randomized retrospective de-
sign is the concern of unequal risk distribution between both
groups. Indeed, due to the fact that PSMA-PET is used rather
in high-risk patients, the PSMA group had a significantly
higher risk before surgery compared with the CI group.
However, despite a significantly higher risk profile, the
PSMA group had a lower PSA persistence rate compared
with the CI group.
The heterogeneous staging in the CI group including cho-
line PET in 45% of the patients is also a limitation. However,
the exclusion of the patients who underwent choline PET be-
fore surgery would have substantially reduced our CI group
and further increased the bias for a higher risk in the PSMA
group, given that 75% of the high-risk patients in the CI group
underwent choline PET. Choline was not widely established
for staging PCa; nevertheless, there is a number of publica-
tions that show a slight superiority or at least non-inferiority of
choline PET compared with CI [23]. We therefore included
patients that had choline PET before RPE for our CI group.
The higher risk profile of the PSMA-PET group as well as
the inclusion of patients who underwent choline PET in the CI
group might have underestimated the potential of PSMA-PET
to improve patient’s oncological outcome in our study.
Therefore, our finding of a better outcome in the PSMA group
warrants further prospective studies to assess the impact of
PSMA-PET on patient outcome and overall survival.
Conclusion
68Ga-PSMA-11 PET has the potential to improve imme-
diate RPE outcome, especially in patients with high-risk
disease, where we showed that patients in the PSMA
group had a significantly lower rate of PSA persistence
after RPE compared with patients that underwent CI.
Looking into all consecutively operated patients, there
was a significant shift of RPE towards higher risk patients
when PSMA-PET was available, without an increase in
R1 resections or PSA persistence.
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